第五周作業(yè)匯 報(bào)

第五周作業(yè)匯報(bào)蔡學(xué)融郭蕾蕾泰爾格王啟圣漢譯英（句子翻譯請(qǐng)?bào)w現(xiàn)英語(yǔ)的靜態(tài)特征）1.然而它的重要性還未被普遍地認(rèn)識(shí)到，有時(shí)甚至造成無(wú)法挽回的損失。譯：However,itsimportancehasnotbeenuniversallyrealizedandsometimesmayresultinirretrievablelosses.修改：However，lackofwidespreadrealizationofitsimportancesometimesmayresultsinirretrievablelosses.2.因?yàn)樗私饧?xì)菌引起啤酒變質(zhì)的道理，所以他相信是某些微生物引起了這些疾病。譯：Hebelievedthatthesediseaseswereinducedbysomemicroorganismbecauseofhisknowledgeofbacteriainducingbeerspoilage.（歧義）修改：Hisknowledgeofbacteriacausingbeerspoilagemakeshimbelievethatthesediseaseswereinducedbysomemicroorganism.漢譯英（句子翻譯請(qǐng)?bào)w現(xiàn)英語(yǔ)的靜態(tài)特征）3.它們不僅對(duì)身體健康很重要，而且還可以有效預(yù)防癌癥，延長(zhǎng)壽命，抑制潰瘍、心臟病發(fā)作和冠狀動(dòng)脈疾病。譯：Theyareimportantnotonlyforgoodhealth,butalsoforcancerprevention,longevity,ulcersinhibition,heartattacksandcoronaryarterydisease.修改：Theyarenotonlyimportanttogoodhealth,butalsoeffectiveincancerprevention,lifeprolonging,ulcerinhibition,heartattacksandcoronaryarterydisease.漢譯英（句子翻譯請(qǐng)?bào)w現(xiàn)英語(yǔ)的靜態(tài)特征）4.(1)如果喪失其中的某些細(xì)胞，比如說(shuō)失去構(gòu)成整條腿的細(xì)胞，將會(huì)嚴(yán)重影響其余所有機(jī)體組織；譯：Lossofsomeofthesecells,suchascellsconstitutinganentireleg,willseverelyimpactalltherestoforganism.修改：Lossofsomeofthesecells,suchasthoseconstitutinganentireleg,willseverelyhandicapalltherestofbodytissues.漢譯英（句子翻譯請(qǐng)?bào)w現(xiàn)英語(yǔ)的靜態(tài)特征）漢譯英（句子翻譯請(qǐng)?bào)w現(xiàn)英語(yǔ)的靜態(tài)特征）4.(2)而像心臟或腎臟之類(lèi)的器官，哪怕相對(duì)較少的細(xì)胞受到嚴(yán)重?fù)p害，也可能會(huì)最終導(dǎo)致所有50萬(wàn)億細(xì)胞的死亡。譯：Andseriousdamagetotherelativelyfewcellsoforganslikeheartandkidneysmayresultinallthe50trillioncells'death.修改：Andseriousdamagetotherelativelyfewcellsoforganslikeheartandkidneysmayresultindeathofallthe50trillioncells.專(zhuān)業(yè)知識(shí)介紹腫瘤靶向治療的藥物傳輸系統(tǒng)用于腫瘤靶向治療的藥物傳輸系統(tǒng)主要由兩部分構(gòu)成，即藥物載體和腫瘤靶向配體。根據(jù)靶向部位的不同，又可將腫瘤靶向配體分為兩大類(lèi)，即腫瘤細(xì)胞靶向配體和腫瘤血管靶向配體。腫瘤細(xì)胞靶向配體是選擇性地與腫瘤細(xì)胞表面的特異性抗原或受體結(jié)合。腫瘤血管靶向配體則是選擇性地與腫瘤區(qū)域新生血管的內(nèi)皮細(xì)胞表面的特異性抗原或受體結(jié)合。DrugDeliverySystemforTumorTargetingTherapyThedrugdeliverysystemfortumortargetedtherapyconsistsoftwoparts,thedrugcarrierandthetumortargetingligand.Tumortargetingligandscanbedividedintotwocategoriesaccordingtothedifferenttargetingsites,namelytumorcelltargetingligandsandtumorvasculartargetingligands.Tumorcell-targetingligandsareselectivelyassociatedwithspecificantigensorreceptorsonthesurfaceoftumorcells.Tumorvasculartargetingligandsselect